Swedish RaySearch Laboratories has received clearance from the FDA for RayStation 3.5 meaning that the new features can be marketed in the US.
RaySearch Laboratories is a medical technology company founded in 2000 as a spin-off from Karolinska Institutet in Stockholm. The company is listed in the Small Cap segment on NASDAQ OMX Stockholm and develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are mainly sold through license agreements with partners such as Philips, Nucletron, IBA Dosimetry, Varian and Accuray. To date, 15 products have been launched through partners and RaySearch’s software is used at over 2,000 clinics in more than 30 countries.
In March RaySearch announced that version 3.5 of RaySearch’s RayStation treatment planning system had been released for clinical use. The most important new features are tools for treatment planning of radiation therapy with electrons and protons, complementing RayStation’s tools for planning and optimization of radiation therapy with photons. Proton Beam Design is a new module in RayStation that contains tools for treatment planning of double scattered and uniformly scanned protons, such as a clinically approved Pencil Beam dose engine and automatic generation of treat-and-protect beams.
“We are of course happy that we now have a complete offering for our US customers, with support for all treatment modalities including protons and electrons, and support all IMRT and VMAT delivery modes with all relevant treatment machines. This new version also includes some highly useful tools to improve the clinical workflow and further expands our market-leading toolbox for adaptive 4D treatments, which I believe further cements RayStation’s position as the most advanced treatment planning system on the US market”, says Johan Löf, CEO of RaySearch in a press release.